Answers are grounded in this paper and cite their sources.
In metabolic engineering, the production of industrially relevant chemicals, via rational engineering of microorganisms, is an intensive area of research. One particular group of microorganisms that is fast becoming recognized for their commercial potential is cyanobacteria. Through the process of photosynthesis, cyanobacteria can use CO 2 as a building block to synthesize carbon-based chemicals. In recent years, clustered regularly interspaced short palindromic repeats (CRISPR)-dependent approaches have rapidly gained popularity for engineering cyanobacteria. Such approaches permit markerless genome editing, simultaneous manipulation of multiple genes, and transcriptional regulation of genes. The drastically shortened timescale for mutant selection and segregation is especially advantageous for cyanobacterial work. In this review, we highlight studies that have implemented CRISPR-based tools for the metabolic engineering of cyanobacteria.
No takes yet. Share an insight, caveat, or question.
Behler et al. (2018) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: